[Remote] Machine Learning Scientist II/Sr (Omics) - UK at Axsome Therapeutics Inc

Roorkee, Uttarakhand, India

Apply Now

Not SpecifiedCompensation

Junior (1 to 2 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, Computational BiologyIndustries

Requirements

The ideal candidate should possess a PhD (or equivalent experience) in machine learning, computational biology, bioinformatics, computer science, or a related field, along with at least 3 years of relevant experience. Demonstrated expertise in applying deep learning to omics data at scale is required, as well as proficiency in Python and modern deep-learning frameworks such as PyTorch or JAX. A solid grasp of causal inference, experimental design, and statistics is also necessary, along with familiarity with software engineering best practices, version control, and continuous integration.

Responsibilities

This Machine Learning Scientist II/Sr (Omics) will identify, prioritize, and acquire multi-omics datasets, build and maintain data pipelines for ingesting and harmonizing large datasets, design schemes for pretraining and finetuning models, define benchmarks for target selection and biomarker tasks, apply causal inference principles to propose experiments, write high-quality code and deploy models, stay current with advancements in machine learning and computational biology, and mentor colleagues in best practices.

Skills

multi-omics data

genomics

transcriptomics

proteomics

metabolomics

data pipelines

benchmarking datasets

causal inference

deep learning

Python

PyTorch

JAX

computational biology

bioinformatics

HPC environments

experimental design

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free